Designer glucocorticoids

Biochemical Pharmacology

Volumn 64, Issue 3, 2002, Pages 355-361

  Miner, Jeffrey N ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

Non steroidal anti inflammatory agent; Selective glucocorticoid receptor modulators; Steroid receptor ligand

Indexed keywords

GLUCOCORTICOID;

ADRENAL INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; DRUG DESIGN; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; INSULIN RELEASE; INSULIN RESISTANCE; MOLECULAR BIOLOGY; MOLECULE; NEUROSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PSYCHOSIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; WEIGHT GAIN;

EID: 0036685418     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01121-8     Document Type: Note

References (44)

1. Absolute oral versus inhaled bioavailability: Significance for inhaled drugs with special reference to inhaled glucocorticoids
2. The relationship between systemic exposure to fluticasone propionate and cortisol reduction in healthy male volunteers
3. The adrenal cortex
4. Hypercortisolism and obesity
5. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: Neuro-endocrine and target tissue-related causes
6. Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients
7. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (First of two parts)
8. Cushing's syndrome
9. Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates
10. Management of acute graft-versus-host disease
11. 4 by purified human neutrophils
12. Stress hormones: Their interaction and regulation
13. The science and therapy of glucocorticoid-induced bone loss
14. The genetics of osteoporosis
15. Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses
16. Hormonal status in normal, osteoporotic and corticosteroid-treated postmenopausal women
17. Cortisol-induced suppression of plasma testosterone in normal adult males
18. Acute adverse reactions to prednisone in relation to dosage
19. The effects of glucocorticoid therapy
20. Mechanisms of dexamethasone-induced insulin resistance in healthy humans
21. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance
22. New connections in the regulation of PEPCK gene expression by insulin
23. Multihormonal regulation of phosphoenolpyruvate carboxykinase gene transcription. The dominant role of insulin
24. The human insulin gene contains multiple transcriptional elements that respond to glucocorticoids
25. Pancreatic β cells are important targets for the diabetogenic effects of glucocorticoids
26. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets
27. Novel glucocorticoid receptor coactivator effector mechanisms
28. Nuclear receptor coactivators
29. PGC-1, a versatile coactivator
30. Regulation of adipogenesis and energy balance by PPARg and PGC-1
31. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression
32. Alien, a highly conserved protein with characteristics of a corepressor for members of the nuclear hormone receptor superfamily
33. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor
34. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor
35. GRIP-1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors
36. Factor recruitment and TIF2/GRIP-1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones
37. Deflazacort. A review of its pharmacological properties therapeutic efficacy
38. Effects of deflazacort on aspects of bone formation in cultures of intact calvariae and osteoblast-enriched cells
39. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit anti-inflammatory activity in vivo
40. New glucocorticosteroids with an improved therapeutic ratio?
41. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity
42. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1
43. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
44. A tissue-specific coactivator of steroid receptors, identified in a functional genetic screen